(HGSH) Reports the Completion of Two Municipal Road Construction Projects

HANZHONG, China, March 24, 2014  — China HGS Real Estate Inc. (NASDAQ: HGSH) (“China HGS” or the “Company”), a leading regional real estate developer headquartered in Hanzhong City, Shaanxi Province, China, today announced that the Hanzhong government accepted the delivery of the two municipal roads that were constructed by the Company on March 21, 2014.

In June 2012, the Company was approved by the Hanzhong local government to construct two municipal roads, namely Mingzhu Road West and Liuhou Road. The related construction was completed and the Hanzhong government performed its quality inspections and accepted these two roads on March 21, 2014. The final construction price for these two roads is approximately $3.16 million (RMB19, 483,589), which was approved by the Hanzhong Ministry of Finance.

Mr. Xiaojun Zhu, China HGS’s Chairman and Chief Executive Officer, said, “We are proud that our team was selected for these two important municipal road construction projects as part of the Hanzhong City Urban Redevelopment Program. We successfully completed these projects on a timely basis. It is a new milestone for the Company, demonstrating our commitment to expand our business to the future of Hanzhong City.”

Forward-looking Statements:

This press release contains certain statements that may include ‘forward-looking statements’. All statements other than statements of historical fact included herein are ‘forward-looking statements’. These forward looking statements are often identified by the use of forward-looking terminology such as ‘believes,’ ‘expects’ or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website http://www.sec.gov. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

About China HGS Real Estate, Inc.

China HGS Real Estate, Inc. (NASDAQ: HGSH), founded in 1995 and headquartered in Hanzhong City, Shaanxi Province, is a leading real estate developer in the region and holds the national grade I real estate qualification. The Company focuses on the development of high-rise, sub-high-rise residential buildings and multi-building apartment complexes in China’s Tier 3 and Tier 4 cities and counties with rapidly growing populations driven by increased urbanization. The Company provides affordable housing with popular and modern designs to meet the needs of multiple buyer groups. The Company’s development activity spans a range of services, including land acquisition, project planning, design management, construction management, sales and marketing, and property management. For further information about China HGS, please go to www.chinahgs.com.

Company contact:

Randy Xiong
President of Capital Market
China Phone: (86) 091-62622612
Email: randy.xiong@chinahgs.com

(PERF) Sofia Vergara Launches Her Premiere Fragrance For Women On HSN

NEW YORK, March 24, 2014  — Sofia Vergara, an international entrepreneur, actress and style icon, enters the fragrance business with the launch of her first scent, SOFIA BY SOFIA VERGARA.  The fragrance makes its debut exclusively with entertainment and lifestyle retailer HSN at 12:01 a.m. on April 24^th and in key markets internationally.  SOFIA will roll out to retailers nationwide in September.  The luxurious new, juicy oriental floral fragrance embodies the actress’ vibrant personality, innate charm and exotic beauty.

“SOFIA BY SOFIA VERGARA is designed for the woman who wants to feel irresistible and truly enjoys being a woman,” says Sofia Vergara. “I wanted to bring a little bit of who I am, my ethnicity and create a fragrance that is a true reflection of me.”

“It was important for Sofia to wait to launch a fragrance until the timing was right,” according to Luis Balaguer, CEO and co-founder of Latin World Entertainment with Sofia Vergara in 1994.  “Sofia wanted to be very involved in the development of the fragrance and we knew it was critical to carefully choose the right partners (Maesa and Parlux), as well as the distribution channels.”

The fragrance is a natural extension of the Sofia Vergara lifestyle brand.  “Sofia has a passion for empowering women to feel good about themselves.  She focuses her brand on creating products that enhance a woman’s life,” says Nancy Overfield-Delmar, President of Latin World Entertainment Licensing.

HSN’s Chief Merchandising Officer Anne Martin-Vachon said, “This fragrance truly embodies Sofía’s captivating personality. She is smart, glamorous, sophisticated, sensual and highly accessible to her fans…all great qualities to have for a successful beauty launch at HSN.”

Passionately constructed with perfumer Bruno Jovanovic (IFF), SOFIA BY SOFIA VERGARA is a sparkling cocktail of exquisite notes. The scent opens with a beautiful berry blend to represent Sofia’s vibrant energy while the middle notes embrace her love for her native country, Colombia. Lastly, the base notes evoke her sexy, provocative magnetism.  The fragrance combines unique ingredients, including:

• TOP NOTES: Blackberry, Sparkling Cassis Buds, Plum
• MID NOTES: Purple Violet, Colombian Rose, Colombian Orchid
• BASE NOTES: Earthy Woods, Vanilla, Sandalwood

“Inspired by Colombia’s native gem and Sofia’s favorite stone – the emerald – the bottle has been carved into a brilliant, multi-faceted form that radiates the extraordinary glamour for which Sofia is known,” explained Scott Oshry, CMO and Partner of Maesa, the branding and manufacturing firm behind the fragrance.  “We’ve created a classic fine fragrance that captures the essence of Sofia.”

Donald Loftus, President of Parlux Ltd. said, “Once we had the right fragrance and packaging, our next step was to find the ideal retail partner.  HSN is the perfect platform to introduce Sofia’s signature fragrance as it allows women the opportunity to enjoy a night in with Sofia and shop with her in the comfort of their own homes.”

Sofia’s bold sensuality is captured in an evocative ad campaign shot by Carter Smith.

The Eau de Parfum will retail for $55 (100ml) and $48 (50ml) and a Shimmer Body Lotion for $30. For more information, visit HSN.com.

ABOUT LATIN WORLD ENTERTAINMENT
Latin World Entertainment is the premiere Hispanic talent management, entertainment-marketing, production and licensing firm in the U.S. LWE represents the biggest stars, opinion makers and trendsetters in the Spanish-speaking entertainment world and leverages that star power to take brands into the burgeoning US Hispanic market.  www.latinwe.com

ABOUT PARLUX FRAGRANCES, LTD
Parlux Fragrances, LTD, a leading global beauty company designs, manufactures, markets and distributes prestige fragrances and related products since 1987.  It holds the licenses for notable fragrance brands including Rihanna, Jessica Simpson, Vince Camuto, Kenneth Cole, JAY Z and Tommy Bahama among others.

Parlux Fragrances, LTD is a wholly owned subsidiary of Perfumania Holdings Inc., an independent, national, vertically integrated wholesale distributor and specialty retailer of fragrances and related products. It is traded on the NASDAQ exchange (PERF).
http://www.parlux.com/

ABOUT MAESA
Maesa is a company that fosters an entrepreneurial spirit, cultivates leadership and encourages innovative thinking. With offices in New York, Los Angeles, Paris, and Dongguan, Maesa’s teams cooperate cross functionally to continually innovate and reinvent products to best serve the global customer. Maesa launches more than 1,000 proprietary products a year and partners with over 100 leading retailers and beauty brands worldwide ranging from fragrance, color cosmetics, bath & body, skincare, haircare, and home. While combining creativity, entrepreneurial vision and proprietary resources, Maesa designs and manufactures private label and exclusive brands for retailers offers branding, design, marketing, packaging and turnkey manufacturing for beauty brands.
http://maesa.com/

(RLOC) Acquires Its Exclusive New Zealand Distributor

ReachLocal, Inc. (NASDAQ:RLOC), a leader in powering local online marketing for small-to-medium sized enterprises (SMEs), today announced its acquisition of the (SME) division of SureFire Search Limited, the exclusive distributor of ReachLocal solutions in New Zealand. The two companies started working together in 2011, when SureFire’s strong New Zealand-based sales team began to exclusively distribute ReachLocal’s leading edge online marketing solution to the local market.

“Surefire has been a fabulous strategic partner and provided us with a seamless way to bring our products to the New Zealand market,” said Josh Claman, President of ReachLocal. “At their current size, it makes good sense to integrate their operations into the rest of our international businesses. We’re excited to take this opportunity to further our expansion in the New Zealand market.”

Following this acquisition, SureFire’s current SME customers will continue to receive the industry-leading ReachLocal products and technology they have come to know and trust.

“The ReachLocal platform was ideally suited for our SME client base,” said Mark Sceats, Managing Director of SureFire Search Ltd. “Our success using the platform in New Zealand confirms the strength of the ReachLocal model. We are very proud of what the team in New Zealand has achieved and our contribution to the business, and we believe that they are on track to build a very significant business here in New Zealand.”

Over the past six years, ReachLocal has established a strong international presence. The company now helps SMEs across 16 countries overcome increasingly complex marketing challenges by providing them with state-of-the-art solutions. Last year, the company’s international revenue grew 41% to represent 38% of its total revenue.

About ReachLocal, Inc.

ReachLocal, Inc. (NASDAQ: RLOC) develops online marketing and transaction solutions that power local commerce for SMBs, from lead generation and lead conversion to booking and buying. Our global distribution network includes local Internet marketing consultants and service professionals, along with select third-party agencies and resellers across 5 continents. ReachLocal is headquartered in Woodland Hills, Calif.

(ICLD) to Acquire Cloud Backup Solutions Provider VaultLogix

Company Strengthens Its Cloud Services Product Offering and Distribution Channels

RED BANK, N.J., March 24, 2014 (GLOBE NEWSWIRE) — InterCloud Systems, Inc. (Nasdaq:ICLD) (“InterCloud” or the “Company”) announced today that it has entered into a Definitive Agreement (the “Agreement”) to acquire cloud solutions company, VaultLogix, LLC. VaultLogix has over $12 million in annual recurring revenue with EBITDA at approximately $4.5 Million.

VaultLogix is a leading provider of hybrid cloud backup services to nearly 10,000 businesses around the world. Their customers benefit from a combination of unique product features, 24×7 customer support and regulatory compliance assistance for the protection of critical business data.

Protecting servers, laptops and PC’s, VaultLogix safeguards a wide range of enterprise-class operating systems and applications through its unique combination of encryption, block-level data duplication and compression. In addition, VaultLogix’s industry leading partner program offers software branding, a robust partner portal, dedicated account management and integration with 13 of the premier RMM and PSA companies.

VaultLogix maintains annual SOC2 Type 2 review of its infrastructure, processes and controls and is GSA certified.

Tim Hannibal, CEO of VaultLogix stated: “Our entire team is very excited about joining InterCloud. We look forward to both selling the VaultLogix services to the impressive InterCloud clientele as well as cross-selling the portfolio of InterCloud services to our existing team of resellers and customers”. Tim Hannibal added: “As the managed services industry evolves, customers are looking toward a single vendor for multiple cloud services. InterCloud’s wide range of cloud services such as IaaS, Virtual Desktop, Hosted Exchange, Disaster Recovery in the cloud and file sharing are highly complementary to the VaultLogix cloud backup service.”

“The acquisition of VaultLogix continues to strengthen InterCloud’s position within the rapidly growing cloud-based services market. VaultLogix has its own intellectual property and will integrate seamlessly with our own cloud platform. In addition it brings InterCloud over 500 channel partners, which will catapult our growing channel sales efforts.  We will continue to broaden our cloud portfolio and differentiate ourselves from our competitors,” said Mark Munro, CEO of InterCloud Systems.

The transaction is expected to close in the next 60 days and is subject to customary closing conditions and acceptable financing terms.

About InterCloud Systems, Inc.

InterCloud Systems, Inc. is a global single-source provider of value-added services for both corporate enterprises and service providers. The company offers cloud and managed services, professional consulting services and voice, data and optical solutions to assist its customers in meeting their changing technology demands. Its engineering, design, installation and maintenance services support the build-out and operation of some of the most advanced enterprise, fiber optic, Ethernet, and wireless networks. Additional information regarding InterCloud may be found on the Company’s website at www.intercloudsys.com.

About VaultLogix, LLC

Since 2002, VaultLogix has specialized in providing businesses with cloud backup and data protection services. The company offers business-class backup solutions to meet the data protection and regulatory requirements of a wide range of companies and organizations. VaultLogix maintains data vaults in Massachusetts, Louisiana and Toronto, Ontario. Visit us at www.dataprotection.com or by calling 877.828.5856.

FORWARD-LOOKING STATEMENTS

The above news release contains forward-looking statements. The statements contained in this document that are not statements of historical fact, including but not limited to, statements identified by the use of terms such as “anticipate,” “appear,” “believe,” “could,” “estimate,” “expect,” “hope,” “indicate,” “intend,” “likely,” “may,” “might,” “plan,” “potential,” “project,” “seek,” “should,” “will,” “would,” and other variations or negative expressions of these terms, including statements related to expected market trends and the Company’s performance, are all “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 and involve a number of risks and uncertainties. These statements are based on assumptions that management believes are reasonable based on currently available information, and include statements regarding the intent, belief or current expectations of the Company and its management. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performances, and are subject to a wide range of external factors, uncertainties, business risks, and other risks identified in filings made by the company with the Securities and Exchange Commission. Actual results may differ materially from those indicated by such forward-looking statements. The Company expressly disclaims any obligation or undertaking to update or revise any forward-looking statement contained herein to reflect any change in the company’s expectations with regard thereto or any change in events, conditions or circumstances upon which any statement is based except as required by applicable law and regulations.   The Private Securities Litigation Reform Act of 1995 (the “PSLRA”) provides a “safe harbor” for forward-looking statements so long as those statements are identified as forward looking and are accompanied by meaningful cautionary statements identifying important factors that could cause actual results to differ materially from those projected in such statements.

CONTACT: Investor Relations
         RedChip Companies, Inc.
         Mike Bowdoin, Vice President
         Mike@redchip.com
         Tel: 407-644-4256

(MVIS) to Supply UPS with Custom PicoP® Display Modules for Package Guidance Application

MicroVision, Inc. (NASDAQ:MVIS), a leader in innovative ultra-miniature projection display technology, today announced that it has agreed to supply customized PicoP^® display modules to UPS, a global leader in logistics, transportation, package delivery and freight forwarding. UPS handles millions of packages in more than 200 countries and territories every day.

MicroVision’s technology is part of a new package guidance application aimed at increasing processing efficiency in real-time package sorting and routing that UPS is deploying in a facility in the United States. PicoP^® display technology was selected for this application due to its ability to operate in industrial environments and its distinguishing performance characteristics including brightness, infinite focus, and variable field of view. The projection module will be paired with UPS scanning systems to improve package sorting processes.

“We are very pleased to be supplying custom PicoP display modules to UPS for its package routing application,” Alexander Tokman, MicroVision president and CEO, said. “As the leader in logistics handling high volumes of packages every day, UPS is the ideal company to deploy advanced projection capabilities to improve package handling processes. We are confident that MicroVision’s PicoP display technology will aid in accuracy and increased efficiency.”

MicroVision has designed a custom display module for UPS that projects information directly onto packages. Because the size of packages coming through the sorting process vary greatly, the infinite focus and variable field of view projection of PicoP display technology make it well-suited for this application. The overall brightness of the laser-based projector module provides easy visibility for the package handlers.

About MicroVision

MicroVision is the creator of PicoP® display technology, an ultra-miniature laser projection solution for mobile consumer electronics, automotive head-up displays and other applications. MicroVision’s patented display technology helps OEMs break down display boundaries and offer enhanced visibility to mobile experiences. Nearly two decades of research has led MicroVision to become an independently recognized leader in the development of intellectual property. MicroVision’s IP portfolio has been recognized by the Patent Board as a top 50 IP portfolio among global industrial companies and is also included in the Ocean Tomo 300 Patent Index. The company is based in Redmond, Wash.

For more information, visit the company’s website at www.microvision.com, on Facebook at www.facebook.com/MicroVisionInc or follow MicroVision on Twitter at @MicroVision.

MicroVision and PicoP are trademarks of MicroVision, Inc. in the United States and other countries. All other trademarks are the properties of their respective owners.

Forward-Looking Statements

Certain statements contained in this release, including those relating to sales and product benefits, and those containing words such as “will” and “confident” are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the company’s forward-looking statements include the following: our ability to raise additional capital when needed; products incorporating our PicoP display engine may not achieve market acceptance, commercial partners may not perform under agreements as anticipated, we may be unsuccessful in identifying parties interested in paying any amounts or amounts we deem desirable for the purchase or license of IP assets, our or our customers failure to perform under open purchase orders; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain additional contract awards; the timing of commercial product launches and delays in product development; the ability to achieve key technical milestones in key products; dependence on third parties to develop, manufacture, sell and market our products; potential product liability claims; and other risk factors identified from time to time in the company’s SEC reports, including the company’s Annual Report on Form 10-K filed with the SEC. Except as expressly required by federal securities laws, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changes in circumstances or any other reason.

(NTK) Positions as Major Supplier, Acquires Thomas & Betts’ HVAC Business

Company Signs Definitive Agreement to Acquire Global Manufacturer of Commercial HVAC Equipment, Including Well-Known Reznor® Brand, for $260 Million in Cash

PROVIDENCE, R.I., March 21, 2014  — Nortek, Inc. (Nasdaq: NTK), a global diversified manufacturer of innovative, air management and technology-driven products and solutions for residential and commercial applications, today announced it has signed a definitive agreement to acquire the heating, ventilation and air conditioning (HVAC) business of Thomas & Betts Corporation, which is a wholly owned subsidiary of ABBLtd (VTX: ABBN), a global power and automation company.  Wells Fargo Securities, LLC served as exclusive financial advisor to Nortek.

Under the terms of the agreement, Nortek will pay approximately $260 million for Thomas & Betts’ HVAC Business (“T&B HVAC”) in an all-cash transaction. T&B HVAC includes Reznor Manufacturing Company, LLC (U.S.), AmbiRad Ltd (U.K.), Reznor Europe, N.V. (Belgium), Gaz Industrie S.A.S. (France) and manufacturing operations in Monterrey, Mexico.

T&B HVAC designs, manufactures and sells unit heaters, radiant heaters and rooftop heating, ventilation and cooling products for industrial and commercial applications primarily in North America and Europe.   Principal end-use applications for T&B HVAC products include warehouses, factories, restaurants, retail locations and institutions and other applications.

Net sales of T&B HVAC were approximately $160 million in 2013. The transaction is expected to close during the second quarter of 2014, subject to customary closing conditions including approval pursuant to the Hart-Scott-Rodino Antitrust Improvements Act of 1976.

“Acquiring this business will enable us to extend our air management business into attractive adjacent segments of the HVAC market in the United States and Europe,” said Nortek President and Chief Executive Officer Michael J. Clarke. “This business will help link three of our five major segments in the air management category, which include our Residential Ventilation (RESV), Residential Heating and Cooling (RHC) and Custom and Engineered Solutions (CES) segments.  In the U.S., we will be adding the well-respected Reznor brand and related products to those of Nordyne’s residential and light commercial brands along with our other well-known brands, such as Broan®, Mammoth® and Huntair®.  In Europe, we will be complementing our Eaton-Williams business with the businesses of AmbiRad and Gaz Industrie. We look forward to welcoming T&B HVAC’s global community of employees and customers into Nortek’s growing worldwide enterprise.”

Nortek intends to finance the purchase price of approximately $260 million, to repay approximately $93 million of outstanding indebtedness under the existing senior secured term loan, and to pay related fees and expenses with proceeds of an approximately $350 million senior secured term loan (the “Term Loan Facility”) and cash on hand. Nortek has received committed financing for the Term Loan Facility from a group of financial institutions including Wells Fargo Bank, National Association; Wells Fargo Securities, LLC; Royal Bank of Canada; RBC Capital Markets; UBS AG Stamford Branch and UBS Securities LLC as set forth in a commitment letter executed contemporaneously with the definitive purchase agreement.

Nortek will host a conference call to discuss the acquisition today, March 21, 2014, at 10:00 a.m. ET. Those who wish to listen to the conference call webcast should visit the “Investors” section of the company’s website, www.nortekinc.com. In addition, the live call can be accessed by dialing (877) 709-8155 or (201) 689-8881 prior to the start of the call. For those who are unable to listen to the live call, the webcast will be archived on the company’s website. An accompanying slide presentation also will be available on the website.

About ABB

ABB (www.abb.com) is a leader in power and automation technologies that enable utility and industry customers to improve performance while lowering environmental impact. The ABB Group of companies operates in around 100 countries and employs about 150,000 people. Thomas & Betts was acquired by ABB in 2012 and is part of ABB’s Low Voltage Products division.

About Nortek

Nortek* is a global, diversified company whose many market-leading brands deliver broad capabilities and a wide array of innovative, air management and technology-driven products and solutions for lifestyle improvement at home and at work. The company’s broad array of offerings includes ventilation products, heating and cooling products, and air management systems, security systems and digital display mounting solutions.

*As used herein, the term “Nortek” refers to Nortek, Inc., together with its subsidiaries, unless the context indicates otherwise. This term is used for convenience only and is not intended as a precise description of any of the separate corporations, each of which manages its own affairs.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements related to Nortek’s proposed acquisition of the heating, ventilation and air conditioning business of Thomas & Betts Corporation. Generally, these statements can be identified by the use of words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “feel,” “intend,” “may,” “plan,” “potential,” “project,” “should,” “will,” or “would” and similar expressions intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These statements are based on Nortek’s current plans and expectations and involve risks and uncertainties that could cause actual future activities and results of operations to be materially different from those set forth in the forward-looking statements. Important factors impacting such forward-looking statements include our ability to close the proposed acquisition of the HVAC business of Thomas & Betts, the availability and cost of certain raw materials (including, among others, steel, copper, packaging materials, plastics, resins, glass, wood and aluminum) and purchased components, freight costs, the level of domestic and foreign construction and remodeling activity affecting residential and commercial markets, interest rates, employment levels, inflation, foreign currency fluctuations, consumer spending levels, exposure to foreign economies, the rate of sales growth, prices, and product and warranty liability claims. Nortek undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise. For further information, please refer to the reports and filings of Nortek with the Securities and Exchange Commission including the description of “risk factors” set forth under 1A in our annual report on Form 10-K, as updated on subsequent quarterly reports on Form 10-Q.

Contact:

Michael Botelho
Vice President, Strategy and Investor Relations
Nortek, Inc.
401.751.1600
michael.botelho@nortekinc.com

(ARCP) Monthly Common Stock and Series F Preferred Stock Dividends for April

Dividends Expected to Continue at Previously Announced Rate Following Spin-off Announcement

NEW YORK, March 21, 2014  — American Realty Capital Properties, Inc. (“ARCP”) (NASDAQ: ARCP) announced today that, pursuant to the prior authorization of its board of directors, ARCP has declared an annualized dividend of $1.00 per share to be paid monthly to stockholders of record at the close of business on the 8^th day of each month, payable on the 15^th day of such month. Accordingly, on April 15, 2014, ARCP will pay a distribution of $0.0833333 per share to stockholders of record at the close of business on April 8, 2014.

Additionally, ARCP will pay a monthly dividend to holders of its 6.70% Series F Cumulative Redeemable Preferred Stock, par value $0.01 per share (“Series F Preferred Stock”), in respect of the period commencing March 15, 2014 through April 14, 2014, on April 15, 2014. Holders of Series F Preferred Stock on April 1, 2014 will be eligible to receive such dividend. The dividend for the Series F Preferred Stock accrues daily on a 360-day annual basis equal to an annualized dividend rate of $1.675 per share, or $0.1395833 per 30-day month.

ARCP expects to continue paying its common stock and Series F Preferred Stock dividends on a monthly basis at the annualized rates noted above, leading up to and following the consummation of the previously announced spin-off of its multi-tenant power and shopping center business.

About ARCP

ARCP is a self-managed publicly traded Maryland corporation listed on The NASDAQ Global Select Market, focused on acquiring and owning single tenant freestanding commercial properties subject to net leases with high credit quality tenants. Additional information about ARCP can be found on its website at www.arcpreit.com. ARCP may disseminate important information regarding it and its operations, including financial information, through social media platforms such as Twitter, Facebook and LinkedIn.

Forward-Looking Statements

Information set forth herein (including information included or incorporated by reference herein) contains “forward-looking statements” (as defined in Section 21E of the Securities Exchange Act of 1934, as amended), which reflect ARCP’s expectations regarding future events. The forward-looking statements involve a number of risks, uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements. Such forward-looking statements include, but are not limited to, market and other expectations, objectives, intentions, any expectations with respect to estimates of growth and ARCP’s ability to consummate its proposed spin-off of its multi-tenant power and shopping center business and, if consummated, achieve the benefits of such transaction. Additional factors that may affect future results are contained in ARCP’s filings with the SEC, which are available at the SEC’s website at www.sec.gov. ARCP disclaims any obligation to update and revise statements contained in these materials based on new information or otherwise.

(FSLR) Moapa Paiute Tribe, LADWP and First Solar Break Ground on 250MW Solar Project

Today, U.S. Senate Majority Leader Harry Reid (NV) joined representatives from the Moapa Band of Paiutes, executives from First Solar, Inc. (Nasdaq: FSLR) and the Los Angeles Department of Water and Power (LADWP), as well as other community, government and energy industry leaders to celebrate the start of construction of the 250 Megawatt (MW)_AC Moapa Southern Paiute Solar Project. The project is located on the Moapa River Indian Reservation just north of Las Vegas, and has a Power Purchase Agreement (PPA) with the LADWP to deliver clean, solar energy for 25 years to the City of Los Angeles.

“Today’s event marks a very important milestone for Nevada, the Moapa Band of Paiutes, and tribal nations throughout the country,” said Reid. “The Moapa Southern Paiute Solar project is the first utility-scale solar project on tribal land and will deliver much needed economic benefits to the Tribe and Nevada. It will also create about 400 construction jobs, and replace dirty energy with clean solar power.”

The power plant, anticipated to be fully operational by the end of 2015, is expected to generate enough clean solar energy to serve the needs of more than 93,000 homes. This amount of renewable energy will displace approximately 313,000 metric tons of carbon dioxide (CO2) annually—the equivalent of taking about 60,000 cars off the road.

The project will play a key role in LADWP’s efforts to build a clean energy future by expanding renewable energy to 33 percent of its total power supply and eliminating coal power. Solar energy from the Moapa plant will contribute 2.4 percent toward LADWP’s renewable energy portfolio. This transformational goal also includes reducing energy use by at least 10 percent through energy efficiency measures; expanding local solar and other forms of distributed generation; initiating a robust demand-response program; and rebuilding local power plants to better integrate renewable energy and be more flexible to meet peak demand.

“The Moapa Southern Paiute Solar Project is a significant step toward the Los Angeles Department of Water and Power’s effort to achieve a major transformation of the city’s power supply—one that has greater reliance on renewable energy resources and zero coal power,” said Marcie L. Edwards, LADWP General Manager.

For the Moapa Band of Paiutes, the utility-scale solar project is an ideal opportunity for the Tribe to create economic opportunities while preserving the land and their cultural heritage. “This is an important step in becoming a leader in Indian Country and will help to create a model for other Tribes to follow,” said Aletha Tom, Chairwoman of the Moapa Paiute Tribal Council. “If our small Tribe can accomplish this, then others can also. There are endless opportunities in renewable energy, and Tribes across the nation have the available land on which to build them.”

Moapa Southern Paiute Solar, LLC (a subsidiary of First Solar Electric, LLC) is the project owner and will construct the project using First Solar’s advanced photovoltaic (PV) thin film solar modules. The project will be built on 2,000 acres of land on the Moapa River Indian Reservation and include an onsite substation and a new 5.5 mile 500 kV transmission line that will connect the project to the existing Crystal Substation, serving energy users in California.

“First Solar is thrilled to celebrate this important milestone with Senator Reid and distinguished guests, and honored to work with the Moapa Band of Paiutes on this landmark project,” said Jim Hughes, CEO of First Solar. “By working together, we will provide jobs and significant economic benefits to the Tribe and Clark County as well as helping LADWP deliver clean, renewable energy to its customers.”

Once the Moapa Southern Paiute Solar facility becomes fully operational, LADWP will be able to repurpose existing transmission systems that now bring high-carbon coal power from Navajo Generating Station. The Moapa plant, along with a second utility-scale solar power plant in that region of Nevada, will enable LADWP to stop receiving coal power from the Navajo plant by the end of 2015, four years before it is required by California state law—reducing greenhouse gas emissions by 8.4 million metric tons (MMT) between 2014 and 2019 cumulatively. The renewable energy from the two solar power projects in Nevada will contribute over 4 percent to LADWP’s goal of 33 percent renewable energy by 2020.

About First Solar, Inc.

First Solar is a leading global provider of comprehensive photovoltaic (PV) solar systems which use its advanced module and system technology. The company’s integrated power plant solutions deliver an economically attractive alternative to fossil-fuel electricity generation today. From raw material sourcing through end-of-life module recycling, First Solar’s renewable energy systems protect and enhance the environment. For more information about First Solar, please visit www.firstsolar.com.

About Moapa Band of Paiutes

The Moapa Band of Paiutes is part of the Southern Paiute Nation with a mission to preserve its homeland, particularly the 72,000 acre Moapa River Indian Reservation, by building an independent and self-governing community and providing opportunities for economic, educational and cultural growth. The Paiutes respect and honor the land and all living things upon it, and the Tribe has the ability to be a front runner in the clean energy field. The Tribe also operates farms, the Moapa Travel Plaza, a sand and gravel operation and has other future plans for expansion at the Valley of Fire area.

About LADWP

The Los Angeles Department of Water and Power is the nation’s largest municipal utility, having provided water and electric service to Los Angeles residents and businesses for over 100 years in an environmentally beneficial manner at competitive rates.

For First Solar Investors

This release contains forward-looking statements which are made pursuant to safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements, among other things, concerning: our business strategy, including anticipated trends and developments in and management plans for our business and the markets in which we operate; future financial results, operating results, revenues, gross margin, operating expenses, products, projected costs, warranties, solar module efficiency and balance of systems (“BoS”) cost reduction roadmaps, restructuring, product reliability and capital expenditures; our ability to continue to reduce the cost per watt of our solar modules; our ability to reduce the costs to construct photovoltaic (“PV”) solar power systems; research and development programs and our ability to improve the conversion efficiency of our solar modules; sales and marketing initiatives; and competition. These forward-looking statements are often characterized by the use of words such as “estimate,” “expect,” “anticipate,” “project,” “plan,” “intend,” “believe,” “forecast,” “foresee,” “likely,” “may,” “should,” “goal,” “target,” “might,” “will,” “could,” “predict,” “continue” and the negative or plural of these words and other comparable terminology. Forward-looking statements are only predictions based on our current expectations and our projections about future events. You should not place undue reliance on these forward-looking statements. We undertake no obligation to update any of these forward-looking statements for any reason. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by these statements. These factors include, but are not limited to, the matters discussed in Item 1A: “Risk Factors,” of our Annual Report on Form 10-K for the year ended December 31, 2012, as updated and supplemented by risk factors included in our Prospectus dated June 12, 2013 filed with the SEC pursuant to Rule 424(b)(5) (the “Prospectus”), Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other reports filed with the SEC.

(HERO) to Present at the Howard Weil 42nd Annual Energy Conference

HOUSTON, March 21, 2014  — Hercules Offshore, Inc. (Nasdaq: HERO) announced today that John T. Rynd, Chief Executive Officer and President, will present at the Howard Weil 42nd Annual Energy Conference in New Orleans, LA, on Tuesday, March 25, 2014, at 10:15 a.m. EDT (9:15 a.m. CDT). An audio replay of the presentation will not be available; however, the slides can be accessed through Hercules Offshore’s website (http://www.herculesoffshore.com) beginning on March 25, 2014.

Headquartered in Houston, Hercules Offshore, Inc. operates a fleet of 38 jackup rigs and 24 liftboats. The Company offers a range of services to oil and gas producers to meet their needs during drilling, well service, platform inspection, maintenance, and decommissioning operations in several key shallow water provinces around the world. For more information, please visit our website at http://www.herculesoffshore.com.

(IDN) Hires New Sales Team to Support Growth Initiatives

Intellicheck Mobilisa, Inc. (NYSE MKT:IDN), a global leader in identity solutions and wireless security systems, has doubled its sales force with the addition of five recent hires. In addition to the new hires, the company has restructured its sales force into vertical markets.

Ms. Elizabeth (Beth) Quinn, Vice President of Sales, Retail & Hospitality and Mr. Charles Weiss, Vice President of Sales, Financial join Mr. Larry McGonagle, Vice President of Sales, Commercial in the Long Island office. Additionally, the hiring of Mr. Eli Goykadosh into the sales and customer support center in the Long Island office will allow Mr. Richard Schabe to transfer into a more active sales-oriented role.

Ms. Kim Chochon, Vice President of Sales, Access Control and Mr. Jason Hollingsworth, Vice President of Sales, Law Enforcement join Mr. Terry Thiele, Vice President of Sales, Government and Ms. Crystal Hudson, Vice President of Sales, Age Verification in the Port Townsend, Washington office.

Continuing its concentration of force in its sales initiative, the company recently promoted Ms. Heather Flanagan to Director of Marketing and Mr. Robert Streett to Director of Sales.

Prior to joining the company, Ms. Flanagan was president of a consulting firm that helped companies with rebuilding sales teams and providing sales training, with a strong focus on sales and marketing processes, customer experience design and executive development. Previously she was a Regional Technical Sales Director at Ramco Electric, where she was responsible for managing distribution chains, technical sales training and customer relations. She received a BA degree in psychology from Whitman College in Walla Walla, Washington and continued with doctoral work in experimental psychology at Western Michigan University in Kalamazoo, Michigan.

Mr. Streett has more than 20 years of experience in sales, account management, customer service and management. His responsibilities include overseeing sales of all of the company’s products including the government and commercial products. Previously at Intellicheck Mobilisa, he served initially as Vice President and subsequently as Deputy Director. He earned a BS degree in business administration and marketing management from California State Polytechnic University.

Dr. Nelson Ludlow, President and CEO of Intellicheck Mobilisa, said, “I look forward to bringing the established team together with our fresh hires and inspiring our new, expanded sales force to take the company to the next level. We are looking for results from these new hires in Q3 and Q4 of this year.”

About Intellicheck Mobilisa

Intellicheck Mobilisa is a leading technology company providing wireless technology and identity systems for various applications, including mobile and handheld access control and security systems for the government, military and commercial markets. Products include the Fugitive Finder system, an advanced ID card access control product currently protecting military bases and secure federal locations; ID Check, a patented technology that instantly reads, analyzes, and verifies encoded data in magnetic stripes and barcodes on government-issued IDs, designed to improve the Customer Experience for the financial, hospitality and retail sectors; and barZapp™, an ID-checking mobile app that allows a user’s smartphone to check an ID card. For more information on Intellicheck Mobilisa, please visit www.icmobile.com.

Safe Harbor Statement

Certain statements in this press release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. When used in this press release, words such as “will,” “believe,” “expect,” “anticipate,” “encouraged,” and similar expressions, as they relate to the company or its management, as well as assumptions made by and information currently available to the company’s management identify forward-looking statements. Actual results may differ materially from the information presented here. Additional information concerning forward-looking statements is contained under the heading of risk factors listed from time to time in the company’s filings with the SEC. We do not assume any obligation to update the forward-looking information.

(ECYT) Merck European CHMP Positive Opinions for VYNFINIT®

Merck and Endocyte Announce European CHMP Positive Opinions for VYNFINIT^® (vintafolide) and Companion Imaging Agents FOLCEPRI^® (etarfolatide) and NEOCEPRI^® (Intravenous (IV) folic acid) in Patients with Platinum-Resistant Ovarian Cancer

Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Endocyte, Inc. (NASDAQ:ECYT), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued positive opinions for the Conditional Marketing Authorisations of VYNFINIT^® (vintafolide) and companion imaging components, imaging agent FOLCEPRI^® (etarfolatide), and NEOCEPRI^® (intravenous (IV) folic acid), for the treatment of adult patients with folate receptor-positive, platinum-resistant, ovarian cancer, in combination with pegylated liposomal doxorubicin (PLD).

“These positive CHMP opinions bring Merck and Endocyte one step closer to providing a personalized approach to address a significant unmet medical need in platinum-resistant ovarian cancer,” said Dr. Eric Rubin, vice president, Clinical Development for Oncology, Merck Research Laboratories. “We want to acknowledge our colleagues at Endocyte for their pioneering work in this field, and look forward to the European Commission completing their review of the applications.”

“Vintafolide is a folate receptor targeted agent, and if approved, would be the first oncology therapeutic to employ an imaging agent as a companion diagnostic for patient selection,” said Ron Ellis, Endocyte’s president and CEO. “Today’s positive CHMP opinions are an important step toward personalizing ovarian cancer management for appropriate patients, and validate our Company’s focus on the development of targeted medicines and companion imaging agents designed to improve patient outcomes.”

Vintafolide is proposed for use in combination with PLD for the treatment of adult patients with platinum-resistant ovarian cancer who express the folate receptor on all target lesions. Folate receptor status should be assessed by a diagnostic medicinal product approved for the selection of adult patients for treatment with vintafolide, using Single Photon Emission Computed Tomography (SPECT) imaging, in combination with Computed Tomography (CT) or Magnetic Resonance Imaging (MRI).

Etarfolatide and IV folic acid are medicinal products proposed for diagnostic use only. Etarfolatide, following radiolabelling with sodium pertechnetate (^99mTc) solution, is proposed for SPECT imaging in combination with CT or MRI, for the selection of adult patients for treatment with vintafolide. Intravenous folic acid would be administrated prior to ^99mTc-etarfolatide for the enhancement of SPECT image quality.

The applications for Conditional Marketing Authorisation for vintafolide, etarfolatide and IV folic acid were submitted based on results in platinum-resistant ovarian cancer patients who express the folate receptor on all target lesions as evaluated in the PRECEDENT Phase 2 study (ClinicalTrials.gov Identifier: NCT00722592).

The CHMP positive opinions will be reviewed by the European Commission (EC). If approved, the EC grants a centralized marketing authorization with unified labeling that is valid in the 28 countries that are members of the European Union, as well as European Economic Area members Iceland, Liechtenstein and Norway. The EC usually issues a final legally binding decision within three months of a CHMP opinion.

About vintafolide, etarfolatide and IV folic acid

Vintafolide is an investigational conjugate of folic acid (vitamin B9) linked to an anti-cancer agent, the potent vinca alkaloid desacetylvinblastine hydrazide (DAVLBH). Since cancer cells generally consume higher levels of folate than normal cells to fuel their growth, some cancer cell types – including ovarian – have high concentrations of the folate receptor on their surface. Vintafolide is designed to selectively target the folate receptor to deliver the anti-cancer agent to the cancerous tissue. Tumors that have high concentrations of the folate receptor are identified by etarfolatide, a non-invasive imaging diagnostic agent. Intravenous folic acid is used with ^99mTc-etarfolatide for the enhancement of image quality.

Vintafolide, etarfolatide and IV folic acid have been granted orphan drug status by the EMA. The U.S. Food and Drug Administration has also granted orphan drug status to vintafolide and etarfolatide. Further evaluation is ongoing in the global PROCEED Phase 3 clinical trial in folate receptor-positive (FR 100%), platinum-resistant ovarian cancer (ClinicalTrials.gov Identifier: NCT01170650). The randomized TARGET Phase 2b study of vintafolide in non-small cell lung cancer has completed enrollment (ClinicalTrials.gov Identifier: NCT01577654), and a Phase 2 study in triple-negative breast cancer is expected to be initiated in Q2 (ClinicalTrials.gov Identifier: NCT01953536).

About Folate Receptor-Positive Platinum-Resistant Ovarian Cancer

In 2012, it was estimated that there would be over 40,000 new cases of ovarian cancer in the European Union. Ovarian cancer is one of the most lethal cancers of the female reproductive system. Overall, approximately 80 percent of patients relapse after first-line, platinum-based, chemotherapy. Platinum-resistant ovarian cancer, also known as PROC, is a challenging disease with a high unmet need for new treatments. This type of cancer recurs within six months of completion of a platinum-containing regimen, the standard of care for ovarian cancer. An estimated 80 percent of platinum-resistant ovarian cancer patients have been found to have folate receptor-positive disease, and approximately 40 percent express the receptor, as detected by etarfolatide, in all of their target tumor lesions (FR 100%). Compared to patients who do not express folate receptors on their tumors, folate receptor-positive patients have been shown to have a poorer overall prognosis.

About Merck

Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com and connect with us on Twitter, Facebook and YouTube.

About Endocyte

Endocyte is a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases. Endocyte uses its proprietary technology to create novel SMDCs and companion imaging agents for personalized targeted therapies. The company’s SMDCs actively target receptors that are expressed or over-expressed on diseased cells, relative to healthy cells. This targeted approach is designed to enable the treatment of patients with highly potent drugs into these cells. The companion imaging agents are designed to identify patients whose disease expresses the molecular target of the therapy and who therefore may be more likely to benefit from treatment. For more information, visit http://www.endocyte.com.

Merck Forward-Looking Statement

This news release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of Merck’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline products that the products will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; Merck’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of Merck’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

Merck undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in Merck’s 2013 Annual Report on Form 10-K and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

Endocyte Forward-Looking Statement

Certain of the statements made in this press release are forward looking, such as those, among others, relating to the company’s expectations for seeking regulatory approval and commercial launch of its products, including any conditional marketing authorization from the EMA, initiation of future clinical trials, and expectations for the receipt of milestones, royalties or other profits from the company’s partnership with Merck. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include risks that the company may experience delays in the completion of its clinical trials (whether caused by competition, adverse events, patient enrollment rates, unavailability of clinical trial materials, regulatory issues or other factors); risks that data from its clinical trials may not be indicative of subsequent clinical trial results; risks related to the safety and efficacy of the company’s product candidates, the goals of its development activities, estimates of the potential markets for its product candidates, estimates of the capacity of manufacturing and other facilities required to support its product candidates, projected cash needs, and expected financial results. More information about the risks and uncertainties faced by Endocyte, Inc. is contained in the company’s periodic reports filed with the Securities and Exchange Commission. Endocyte, Inc. disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

VYNFINIT^® is a registered trademark of Merck & Co., Inc., Whitehouse Station, N.J., USA.

FOLCEPRI^® and NEOCEPRI^® are registered trademarks of Endocyte, Inc.

(BEAT) Acquires Cardiac Patient Services Business of BMS

MALVERN, Penn., March 20, 2014  — BioTelemetry, Inc. (Nasdaq:BEAT), the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care, announced that it has entered into a definitive agreement to acquire the cardiac patient services business of Biomedical Systems, Corp. (“BMS”) for aggregate consideration of $8.65 million at closing. Post integration, the acquisition is expected to generate $8.0 to $9.0 million in revenue and $2.5 to $3.0 million in EBITDA on an annualized basis. The transaction is expected to close in early April.

All assets necessary to run the Holter, cardiac event and mobile telemetry service lines are transferring to BioTelemetry, including the Century Holter Analysis System, a fast and accurate software platform with multiple configurations designed to satisfy the needs of small and large volume accounts. The analysis software works seamlessly with the full line of BioTelemetry Holter recorders, including the recently FDA-cleared 14-day Holter, CardioKey.

Joseph H. Capper, President and Chief Executive Officer of BioTelemetry, commented: “We are excited to welcome another respected cardiac monitoring service provider into the BioTelemetry family and look forward to building upon their longstanding relationships with healthcare providers. As we have previously discussed, we see consolidation of like-kind businesses as an excellent way to accelerate our strategic plan. In addition to the benefits of cost-side synergies and market share expansion, this acquisition comes with an excellent Holter software platform essential for the pending launch of CardioKey, as well as a small operation in Europe, providing a base from which to explore international growth opportunities. This acquisition further demonstrates our commitment to achieving sustained long-term growth by solidifying our leadership position in remote cardiac monitoring.”

BMS Chief Executive Officer, Timothy R. Barrett, added:  “We believe BioTelemetry to be the perfect fit as we entrust them to build upon our strong reputation of providing superior cardiac monitoring services directly to the physician and patient. This divestment aligns with Biomedical Systems’ strategy to concentrate on its core business, clinical trials, which has been experiencing tremendous growth over the last decade.”

About Biomedical Systems

Biomedical Systems is a worldwide provider of centralized clinical trial services and cardiac monitoring solutions. Since 1975, Biomedical Systems has provided cardiologists, clinics, and hospitals with ECG monitoring solutions including Holter monitoring, cardiac event monitoring, and 12 lead ECG services. Clinical trial services include cardiac safety, pulmonary function, scientific affairs, medical imaging, neurophysiology, digital pathology, and electronic patient reported outcomes.

About BioTelemetry

BioTelemetry, Inc., formerly known as CardioNet, Inc., is the leading wireless medical technology company focused on the delivery of health information to improve quality of life and reduce cost of care. The company currently provides cardiac monitoring services, original equipment manufacturing with a primary focus on cardiac monitoring devices and centralized cardiac core laboratory services. More information can be found at www.biotelinc.com.

BioTelemetry’s Cautionary Statement Regarding Forward-Looking Statements

This document includes certain forward-looking statements within the meaning of the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995 regarding, among other things, our expectations regarding the success of the BMS transaction and related effect on the Company’s operations. These statements may be identified by words such as “expect,” “anticipate,” “estimate,” “intend,” “plan,” “believe,” “promises” and other words and terms of similar meaning. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including important factors that could delay, divert, or change any of these expectations, and could cause actual outcomes and results to differ materially from current expectations. These factors include, among other things, effects of changes in health care legislation, effectiveness of our cost savings initiatives, relationships with our government and commercial payors, changes to insurance coverage and reimbursement levels for our products, the success of our sales and marketing initiatives, our ability to attract and retain talented executive management and sales personnel, our ability to identify acquisition candidates, acquire them on attractive terms and integrate their operations into our business, the commercialization of new products, market factors, internal research and development initiatives, partnered research and development initiatives, competitive product development, changes in governmental regulations and legislation, the continued consolidation of payors, acceptance of our new products and services, patent protection, adverse regulatory action, litigation success, our ability to successfully create a new holding company structure and to anticipate the benefits of such structure. For further details and a discussion of these and other risks and uncertainties, please see our public filings with the Securities and Exchange Commission, including our latest periodic reports on Form 10-K and 10-Q. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise.

CONTACT: BioTelemetry, Inc.
         Heather C. Getz
         Investor Relations
         800-908-7103
         investorrelations@biotelinc.com

(TSEM) Definitive Agreements with Existing Institutional Bondholders

TowerJazz, the global specialty foundry leader, today announced that it has signed definitive agreements with certain existing US and offshore institutional holders, pursuant to which Jazz Technologies, Inc. will issue new un-secured bonds due December 2018 (the “new bonds”) in exchange for approximately $45 million in aggregate principal amount of the approximately $94 million aggregate principal amount of 8% senior bonds due June 2015. The new bonds will be unsecured and are therefore structurally subordinated to the Wells Fargo credit line of up to $70 million due 2018, as are the currently outstanding bonds due June 2015.

In addition, certain of the participating bondholders have agreed to purchase approximately $10 million principal amount of the new bonds maturing 2018. These transactions will strengthen TowerJazz’s balance sheet by reducing net debt due through June 2015 by approximately $55 million, comprised of an increase of approximately $10 million in its cash balance and a reduction of the bonds due June 2015 from approximately $94 million to approximately $49 million.

The new bonds, which will mature December 31, 2018, carry an 8% coupon payable in cash in two semi-annual installments through maturity and may be converted into ordinary shares of Tower at $10.07 per share, reflecting a 20 percent premium over the average closing price for the Company’s ordinary shares for the five trading days ended one day prior to signing date of these agreements. The new Jazz bonds will not be guaranteed by Tower Semiconductor Ltd.

Oren Shirazi, TowerJazz chief financial officer, said: “This exchange and new note purchase with certain of our US and offshore existing bondholders is another vote of confidence from the investment community for our company and our long-term strategy. The $70 million Wells Fargo credit line extension we signed a few months ago, together with this transaction, are instrumental in enabling TowerJazz to execute on its strategic growth plan and further improve our balance sheet and financial position.”

Russell Ellwanger, chief executive officer, summarized: “This bonds restructuring, together with the recently announced India cabinet decision on the 300mm fab establishment, the pending Panasonic joint venture which is expected to close within a few weeks, and our previously announced Q4 2013 year-over-year 25% organic growth, demonstrates a company actively making progress on its core business, creative M&A/Joint Venture, financials and balance sheet. The end result is a stronger company serving a continually growing customer base producing model shareholder value.”

The consummation of the transaction contemplated by the exchange and note purchase agreements is subject to certain routine regulatory consents and satisfaction of customary closing conditions. The new bonds will be issued at the closing of the exchange transaction, which is expected to occur by the end of this month.

The exchange and note purchase transactions have not been registered and will not be registered under the Securities Act of 1933, as amended, and the securities offered in the exchange may not be offered or sold in the United States absent registration or an applicable exemption from registration. These transactions are being entered into with the participating bondholders in reliance upon applicable exemptions from the registration requirements of the Securities Act of 1933, as amended. This press release is not an offer to exchange or a solicitation of an offer to exchange any securities.

About TowerJazz

Tower Semiconductor Ltd. (NASDAQ: TSEM, TASE: TSEM), its fully owned U.S. subsidiary Jazz Semiconductor Ltd., and its fully owned Japanese subsidiary TowerJazz Japan, Ltd., operate collectively under the brand name TowerJazz, the global specialty foundry leader. TowerJazz manufactures integrated circuits, offering a broad range of customizable process technologies including: SiGe, BiCMOS, Mixed-Signal/CMOS, RFCMOS, CMOS Image Sensor, Power Management (BCD), and MEMS capabilities. TowerJazz also offers clients a world-class design enablement platform, providing a quick and accurate design cycle. In addition, TowerJazz provides (TOPS) Technology Optimization Process Services to IDMs and fabless companies that need to expand capacity. TowerJazz offers multi-fab sourcing with two manufacturing facilities located in Israel, one in the United States and one in Japan. Additional information is available at www.towerjazz.com.

Safe Harbor Regarding Forward-Looking Statements

This press release includes forward-looking statements, which are subject to risks and uncertainties. Actual results may vary from those projected or implied by such forward-looking statements. A complete discussion of risks and uncertainties that may affect the accuracy of forward-looking statements included in this press release or which may otherwise affect TowerJazz’s business is included under the heading “Risk Factors” in Tower’s most recent filings on Forms 20-F, F-3 and 6-K, as were filed with the Securities and Exchange Commission (the “SEC”) and the Israel Securities Authority and Jazz’s most recent filings on Forms 10-K and 10-Q, as were filed with the SEC, respectively. Tower and Jazz do not intend to update, and expressly disclaim any obligation to update, the information contained in this release.

(LIVE) Technology to Be Valued on Its Future Potential in the Online Deal Industry

(BGMD) Patent Covering Galectin-3 Testing for Cardiac Resync Therapy

WALTHAM, Mass., March 20, 2014  — BG Medicine, Inc. (Nasdaq:BGMD) today announced that on March 18, 2014, the United States Patent and Trademark Office issued patent 8,672,857, titled “Galectin-3 and Cardiac Resynchronization Therapy,” to the Company. The patent claims methods for predicting responsiveness to cardiac resynchronization therapy by the measurement of the concentration of the protein galectin-3 in blood.

Cardiac resynchronization therapy, also referred to as biventricular pacing, involves the implantation of a specialized pacemaker device to attempt to improve the heart’s rhythm and alleviate symptoms associated with arrhythmia in heart failure.

“The issuance of this patent both strengthens and broadens BG Medicine’s patent portfolio covering galectin-3 testing,” said Dr. Paul R. Sohmer, President and CEO of BG Medicine, Inc. “We will continue to aggressively pursue the protection of our intellectual property related to galectin-3.”

The BGM Galectin-3® Test is cleared by the U.S. FDA as an aid in assessing the prognosis of patients diagnosed with chronic heart failure when used in conjunction with clinical evaluation.

The BGM Galectin-3® Test is CE Marked and is available in Europe as an aid in assessing the prognosis of patients diagnosed with acute and chronic heart failure when used in conjunction with clinical evaluation. It is also CE Marked for adults as an aid in assessing the risk of new onset heart failure.

About Galectin-3 and Heart Failure

Galectin-3 is a protein that is involved in fundamental disease processes including the development of fibrosis in organ tissues, and cardiac remodeling, which may lead to the development and progression of heart failure. Higher levels of galectin-3 are associated with a more aggressive form of heart failure, which may make identification of high-risk patients using galectin-3 testing an important part of patient care. Galectin-3 testing may be useful in helping physicians determine which patients are at higher risk of hospitalization or death. The BGM Galectin-3® Test is to be used as an aid in assessing the prognosis of patients with chronic heart failure, in conjunction with clinical evaluation. For more information please visit www.BG-Medicine.com.

About BG Medicine, Inc.

BG Medicine, Inc. (Nasdaq:BGMD), the developer of the BGM Galectin-3® Test, is focused on the development and delivery of diagnostic solutions to aid in the clinical management of heart failure and related disorders. For additional information about BG Medicine, heart failure and galectin-3 testing, please visit www.BG-Medicine.com.

The BG Medicine Inc. logo is available for download here

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding: our belief that the issuance of this new patent strengthens and broadens our patent portfolio for galectin-3 testing and our plan to aggressively pursue the protection of our intellectual property related to galectin-3. These forward-looking statements are neither promises nor guarantees of future performance, and are subject to a variety of risks and uncertainties, many of which are beyond the Company’s control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. These risks and uncertainties include, among other things, the factors discussed under the heading “Risk Factors” contained in BG Medicine’s annual report and quarterly reports filed with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and BG Medicine disclaims any obligation to update the information contained in this press release as new information becomes available.

CONTACT: Corporate Communications
         +1 (781) 890-1199
         BG Medicine, Inc.

(ZIOP) to Present at the 21st Annual Future Leaders in the Biotech Industry Conference

BOSTON, March 20, 2014  — ZIOPHARM Oncology, Inc. (Nasdaq:ZIOP) today announced that Francois Lebel, M.D., Senior Vice President, Clinical Development and Medical Operations, will present at the 21^st Annual Future Leaders in the Biotech Industry Conference on Friday, March 28th, 2014 at 3:00 p.m. ET at the Millennium Broadway Hotel in New York City.

To access a live audio webcast of the presentation, please visit the Investor Relations section at www.ziopharm.com. The webcast will be archived for 90 days.

About ZIOPHARM Oncology, Inc.:

ZIOPHARM Oncology is a Boston, Massachusetts-based biotechnology company employing novel gene expression and control technology to deliver DNA for the treatment of cancer. ZIOPHARM’s technology platform employs Intrexon Corporation’s RheoSwitch Therapeutic System® technology to turn on and off, and precisely modulate, gene expression at the cancer site in order to improve the therapeutic index. This technology is currently being evaluated in Phase 2 clinical studies of the immune system cytokine interleukin-12 for the treatment of breast cancer and advanced melanoma. Multiple new Investigational New Drug applications for new targets using synthetic biology technology are expected through 2015. ZIOPHARM is also developing novel small molecules as potential cancer therapeutics.

CONTACT: Lori Ann Occhiogrosso
         ZIOPHARM Oncology, Inc.
         646-214-0702
         locchiogrosso@ziopharm.com

(MNGA) Fuel Selected for Four Demolition Projects

TAMPA, Fla., March 20, 2014  — MagneGas Corporation (“MagneGas” or the “Company”) (NASDAQ: MNGA), the developer of a technology that converts liquid waste into hydrogen-based fuels announced today that it is providing four demolition projects with MagneGas fuel for their torch cutting. These projects are sourced through existing MagneGas distributors Blue Water Industrial of Michigan and AWISCO Corp of New York.  MagneGas fuel will be used in the demolition of a bridge in Washington, DC, automobile manufacturing facilities in Ohio and Michigan and a power plant in New York.

“We are very pleased to be the preferred fuel for cutting on these demolition jobs,” stated Executive Vice President of Sales, Terry Vernille. “With the help of two major distributors, Blue Water Industrial and AWISCO Corp, we have the capability of providing our fuel for these key projects. As word continues spreading in the demolition industry about our superior cutting fuel we expect an increased demand around the country.”

“Since bringing MagneGas to AWISCO we have gained positive traction in the market,” stated Victor Furhman Vice President of Sales and Marketing for AWISCO Corp, “Having the ability to supply a better alternative metal cutting fuel in the market for customers is an added benefit for AWISCO. This customer in New York was already a customer of MagneGas in Florida so it was an easy transition switching them over from acetylene.”

“Our customer in Ohio has used MagneGas fuel on multiple job sites already and continues the demand on future projects,” stated Steve Olson, Vice-President of Blue water Industrial. “As word continues to get out with the improved production and speed of cut we expect the demand for MagneGas to continue upwards.”

The MagneGas IR App is now available for free in Apple’s App Store for the iPhone or iPad http://bit.ly/AfLYww and at Google Play http://bit.ly/Km2iyk for Android mobile devices.

To be added to the MagneGas investor email list, please email pcarlson@kcsa.com with MNGA in the subject line.

About MagneGas Corporation

Founded in 2007, Tampa-based MagneGas Corporation (NASDAQ: MNGA) is the producer of MagneGasTM, a natural gas alternative and metal working fuel that can be made from certain industrial, municipal, agricultural and military liquid wastes following the receipt of appropriate governmental permits.

The Company’s patented Plasma Arc Flow™ process gasifies liquid waste, creating a clean burning hydrogen based fuel that is essentially interchangeable with natural gas. MagneGas can be used for metal working, cooking, heating, powering bi-fuel automobiles and more. For more information on MagneGas, please visit the Company’s website at www.magnegas.com.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements as defined within Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  These statements relate to future events, including our ability to raise capital, or to our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond our control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects our current views with respect to future events and is subject to these and other risks, uncertainties and assumptions relating to our operations, results of operations, growth strategy and liquidity. We assume no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. The Company is currently using new ethylene glycol to produce fuel until proper permits to process used liquid waste have been obtained.

For a discussion of these risks and uncertainties, please see our filings with the Securities and Exchange Commission. Our public filings with the SEC are available from commercial document retrieval services and at the website maintained by the SEC at http://www.sec.gov.

(SYMX) Zhangjiagang Chemical Machinery 20-Year License, China Clean Coal Gasification

HOUSTON, March 19, 2014  — Synthesis Energy Systems, Inc. (SES) (Nasdaq:SYMX) today announced that its wholly owned subsidiary, SES Asia Technologies, Ltd., and Zhangjiagang Chemical Machinery Co., Ltd. (“ZCM”) (Shenzhen listing code: 002564) have successfully completed a major step in the governmental approval process with the receipt of the required 20-year business license on March 18, from the State Administration for Industry & Commerce of the People’s Republic of China (SAIC) in Zhangjiagang, for the previously announced joint venture, ZCM-SES Sino-U.S. Clean Energy Technologies Limited (“ZCM-SES” or the “JV”). Within the next 30 days ZCM is scheduled to make its first cash capital contribution of RMB 53.8 million (approximately US$8.7 million) and SES is to complete its contribution authorizing SES Gasification Technology usage by the JV. Remaining customary government approvals entail the issuance of a verification report, by an independent accountant, of the registered capital contributions. Once the registered capital of the Company has been contributed, and upon the issuance of the final capital contribution certificates, ZCM-SES will be operational.

“Along with our joint venture partner, ZCM, we are pleased to be proceeding smoothly with China government approvals. ZCM has already been working diligently on securing the first orders for ZCM-SES, and we have been working in parallel to ensure a seamless transition of our Shanghai team into the new joint venture,” said Robert Rigdon, SES President and CEO. “A ZCM-SES general manager has been selected, and will be named after an upcoming meeting of the JV’s Board of Directors.”

ZCM has agreed to contribute a total of RMB 100 million (approximately US$16.5 million) to the JV to fund its working capital needs for a 65% ownership interest. ZCM will have exclusive manufacturing rights for all ZCM-SES customer projects in China as well as the joint venture’s additional markets of Indonesia, Malaysia, Mongolia, the Philippines, and Vietnam. SES is contributing exclusive usage of its premiere SES Gasification Technology in these Asian markets for a 35% interest in ZCM-SES.

ZCM-SES was formed to deliver a comprehensive clean coal gasification solution to China and select Asian markets, to advance the region’s development plans. The JV combines SES Gasification Technology with the market reach of one of China’s leading and most respected coal-chemical equipment manufacturers. The uniquely competitive and high growth ZCM-SES clean coal gasification platform coincides with the recent announcement, by the director of the Shanxi State-owned Assets Supervision and Administration Commission at the 12^th National People’s Congress, of the planned formation of a large coal to gas, liquids, glycols and olefins base to provide clean energy to North China.

About Synthesis Energy Systems, Inc.

Synthesis Energy Systems (SES) is a Houston-based technology company focused on bringing clean high-value energy to developing countries from low-cost and low-grade coal, biomass and wastes through its proprietary gasification technology based upon U-Gas®, licensed from the Gas Technology Institute. The SES Gasification Technology enables greater fuel flexibility for both large-scale and efficient small- to medium-scale operations close to fuel sources. Fuel sources include low-rank, low-cost high ash, high moisture coals, which are significantly cheaper than higher grade coals, many coal waste products, and biomass feedstocks. For more information, please visit: www.synthesisenergy.com.

About Zhangjiagang Chemical Machinery Co., Ltd.

Zhangjiagang Chemical Machinery Co., Ltd. is the leading manufacturer of pressure vessels in China and a leading equipment supplier to the coal and chemical sectors. It has served China’s petro-chemical, coal-chemical, refinery, metallurgy, green energy, nuclear and offshore industries for more than four decades. ZCM has more than 3,000 employees across its four manufacturing plants: Linjiang and Chengyang Plants located in Zhangjiagang, Jiangsu Province; Urumchi and Ili Plants located in the Sinkiang Autonomous Area. It also owns and operates port facilities on the Yangtze River, 100km west of Shanghai. ZCM has received certifications from the H.S.E (Health, Safety, & Environment) and ASME (American Society of Mechanical Engineers). Their clients include Shell, GEA, CB&I, Lurgi, Halder Topsoe, KBR, BP, Mitsubishi, SINOPEC, CNPC, and CNOOC. ZCM is a publicly listed company, listed on the Shenzhen Exchange since 2011 (Shenzhen listing code: 002564). For more information, please visit: www.zcmchina.com

Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are subject to certain risks, trends and uncertainties that could cause actual results to differ materially from those projected. Among those risks, trends and uncertainties are the development stage of the operations of SES; the ability of the ZZ joint venture to effectively operate XE’s methanol plant and produce methanol; the ability of the Yima project to produce earnings and pay dividends; the ability of SES to complete the approval process with ZCM for their joint venture and then to develop and expand business in the joint venture territory; its ability to develop its power business unit and marketing arrangement with GE and its other business verticals, steel and renewables; its ability to successfully develop its licensing business; its ability to reduce operating costs; the limited history and viability of its technology; commodity prices and the availability and terms of financing opportunities; the ability of SES to obtain the necessary approvals and permits for future projects; its ability to raise additional capital and its estimate of the sufficiency of existing capital sources; the sufficiency of internal controls and procedures; and its results of operations in foreign countries where it is developing projects. Although Synthesis Energy Systems believes that in making such forward-looking statements its expectations are based upon reasonable assumptions, such statements may be influenced by factors that could cause actual outcomes and results to be materially different from those projected. Synthesis Energy Systems cannot assure you that the assumptions upon which these statements are based will prove to have been correct.

Contact:

MDC Group

Investor Relations:
David Castaneda
Arsen Mugurdumov
414.351.9758
IR@synthesisenergy.com

Media Relations:
Susan Roush
747.222.7012
PR@synthesisenergy.com

(OBCI) Declares Special Cash Dividend: $0.05 per/share

Shareholder Loyalty Rewarded

FORT LAUDERDALE, Fla., March 19, 2014  — Ocean Bio-Chem, Inc. (NASDAQ: OBCI), a leading manufacturer and distributor of appearance, performance, and maintenance products serving the marine, automotive, power sports, recreational vehicle and outdoor power equipment markets, announced today that its Board of Directors declared a special cash dividend of $0.05 per share, payable on April 15, 2014 to shareholders of record on April 1, 2014.

“We are very pleased to be able to provide to our shareholders the first cash dividend in our Company’s history, said Peter Dornau, Ocean Bio-Chem’s President and Chief Executive Officer. “This dividend demonstrates Ocean Bio-Chem’s strong financial condition and our commitment to increasing shareholder value.”

About Ocean Bio-Chem, Inc.:
Ocean Bio-Chem, Inc. is principally engaged in the manufacturing, marketing and distribution of a broad line of appearance and maintenance products for boats, recreational vehicles, automobiles, power sports, outdoor power equipment and motorcycle markets under the Star brite® StarTron® and other trademarks within the United States of America and Canada. In addition, the Company produces private label formulations of many of its products for various customers and provides custom blending and packaging services for these and other products.

The Company trades publicly under NASDAQ Capital Markets, Ticker Symbol: OBCI.

The Company’s web sites are: www.oceanbiochem.com, www.starbrite.com  www.startron.com, and www.nos-guard.com

Forward-looking Statements:
Certain statements contained in this Press Release constitute forward-looking statements. For this purpose, any statements contained in this report that are not statements of historical fact may be deemed forward-looking statements. Without limiting the generality of the foregoing, words such as “believe,” “may,” “will,” “expect,” “anticipate,” “intend,” or “could,” including the negative or other variations thereof or comparable terminology, are intended to identify forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors which may cause actual results to be materially different from those expressed or implied by such forward-looking statements. Factors that may affect these results include, but are not limited to, the highly competitive nature of our industry; reliance on certain key customers; changes in consumer demand for marine, recreational vehicle and automotive products; advertising and promotional efforts; exposure to market risks relating to changes in interest rates, foreign exchange rates, prices for raw materials that are petroleum or chemical based and other factors.

Contact:

Peter Dornau
CEO and President
pdornau@starbrite.com
954-587-6280

Jeff Barocas
Vice President & CFO
Jbarocas@starbrite.com
954-587-6280

Paul Knopick
E & E Communications
pknopick@eandecommunications.com
940-262-3584

(FSLR) Sets Thin-Film Module Efficiency World Record of 17.0 Percent

First Solar, Inc. (Nasdaq: FSLR) today announced it has set a world record for cadmium-telluride (CdTe) photovoltaic (PV) module conversion efficiency, achieving a record 17.0 percent total area module efficiency in tests performed by the U.S. Department of Energy’s National Renewable Energy Laboratory (NREL). The new record is an increase over the prior record of 16.1 percent efficiency, which the company set in April 2013. This announcement comes weeks after First Solar announced it achieved a world record in CdTe research cell efficiency of 20.4 percent.

The record-setting module was created at First Solar’s Research and Development Center in Perrysburg, Ohio, using production-scale processes and materials, and included several recent technology enhancements that are incrementally being implemented on the company’s commercial production lines.

Notably, the First Solar research module also has a confirmed “aperture area” conversion efficiency of 17.5 percent. Many manufacturers often quote this aperture area efficiency when claiming record performance, particularly for small mini-modules custom-built in R&D labs. First Solar’s record is all the more significant because it is full production size.

“This achievement demonstrates our ability to rapidly and reliably transfer research results to full-size modules. We can take CdTe innovation from the lab to production faster and more reliably than other technologies due to our robust, adaptable manufacturing processes and the accommodating nature of CdTe material technology,” said Raffi Garabedian, First Solar’s Chief Technology Officer. “Our R&D efforts are delivering technology that will quickly be scaled to real-world application as part of our integrated power plant systems, which are engineered to deliver the best performance, reliability and value for our customers.”

Garabedian said the efficiency milestone is also a signal that First Solar’s CdTe modules are becoming a more attractive option for application in constrained space projects and commercial/industrial installations. “With the highest demonstrated thin-film module performance, we are positioned to pursue new deployment opportunities around the world,” he said.

Based on the company’s sustained high velocity in technology development, Garabedian said First Solar has accelerated its production module conversion efficiency roadmap, raising its lead-line production nameplate efficiency target for YE2015 to 15.6 to 15.8 percent. First Solar also extended its module conversion efficiency roadmap to 2017, with targets for year-end lead-line production nameplate efficiency of 17.7 to 18.4 percent in 2016 and 18.1 to 18.9 percent in 2017.

About First Solar, Inc.

First Solar is a leading global provider of comprehensive photovoltaic (PV) solar systems which use its advanced module and system technology. The company’s integrated power plant solutions deliver an economically attractive alternative to fossil-fuel electricity generation today. From raw material sourcing through end-of-life module recycling, First Solar’s renewable energy systems protect and enhance the environment. For more information about First Solar, please visit www.firstsolar.com.

For First Solar Investors

This release contains forward-looking statements which are made pursuant to safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include statements, among other things, concerning: our business strategy, including anticipated trends and developments in and management plans for our business and the markets in which we operate; future financial results, operating results, revenues, gross margin, operating expenses, products, projected costs, warranties, solar module efficiency and balance of systems (“BoS”) cost reduction roadmaps, restructuring, product reliability and capital expenditures; our ability to continue to reduce the cost per watt of our solar modules; our ability to reduce the costs to construct photovoltaic (“PV”) solar power systems; research and development programs and our ability to improve the conversion efficiency of our solar modules; sales and marketing initiatives; and competition. These forward-looking statements are often characterized by the use of words such as “estimate,” “expect,” “anticipate,” “project,” “plan,” “intend,” “believe,” “forecast,” “foresee,” “likely,” “may,” “should,” “goal,” “target,” “might,” “will,” “could,” “predict,” “continue” and the negative or plural of these words and other comparable terminology. Forward-looking statements are only predictions based on our current expectations and our projections about future events. You should not place undue reliance on these forward-looking statements. We undertake no obligation to update any of these forward-looking statements for any reason. These forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to differ materially from those expressed or implied by these statements. These factors include, but are not limited to, the matters discussed in Item 1A: “Risk Factors,” of our Annual Report on Form 10-K for the year ended December 31, 2012, as updated and supplemented by risk factors included in our Prospectus dated June 12, 2013 filed with the SEC pursuant to Rule 424(b)(5) (the “Prospectus”), Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other reports filed with the SEC.

(DPW) awarded major military contract for the Israel Aerospace Industries

FREMONT, Calif., March 19, 2014  — Digital Power Corporation (NYSE: DPW) has been awarded a 5-year contract to provide its low voltage power supply (LVPS) multiple outputs DC/DC converter to Israel Aerospace Industries (IAI).

The contract awarded to Digital Power Corporation covers the manufacturing and delivery of the LVPS modules to IAI from 2014 through 2018. IAI will use the LVPS to power the TAMAM Modular Azimuth Position System (TMAPS) navigation system, which is used by the Israel Defense Forces (IDF) in tactical warfare.

Designed to operate in GPS-disturbed or jammed battlefield scenarios, the LVPS features a persistent capability that will provide the TMAPS with continuous and stable power through multiple power sources in the harshest operating conditions.

Amos Kohn, president and CEO of Digital Power Corporation comments, “We are proud that our LVPS product and manufacturing capabilities have been qualified for this effort. The TMAPS represents one of the most significant self-contained hybrid land navigation systems designed to provide autonomous position initialization and moving base alignment for land and amphibious vehicles in the battlefield.”

Continued Mr. Kohn, “The cost-effective LVPS is suitable for installation on a wide range of platforms, such as self-propelled guns, artillery radars, rocket launchers, mortars, observation vehicles and other vehicles types, and is designed for use in varied combat situations. The LVPS is a critical part of a system that provides ground forces with the persistent capability to determine precise position and direction in all weather conditions without requiring a battlefield survey.”

About Digital Power Corporation

Headquartered in Fremont, Calif., Digital Power Corporation designs, manufactures and sells high-grade customized and off-the-shelf power system solutions. Its products are used in the most demanding telecom, industrial, medical and military applications where customers demand high density, high efficiency and ruggedized power solutions. Its wholly owned subsidiary, Digital Power Limited, is based in Salisbury, UK.

Contact: Digital Power Corporation, 48430 Lakeview Blvd., Fremont, California 94538.

1-866-344-7697 E-mail: sales@digipwr.com Website: www.digipwr.com.

(ISR) World’s 1st Pediatric Cesium-131 Seeded Mesh for Metastatic Wilms Tumor

IsoRay Inc. (NYSE MKT: ISR) (http://www.isoray.com/), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced another milestone – the treatment of a pediatric patient’s tumor utilizing multiple Cesium-131 sutured seed meshes for internal radiation therapy.

Dr. Anthony Crimaldi at Levine Cancer Institute, Charlotte, NC, successfully completed the world’s first pediatric implant using IsoRay Medical’s Cesium-131 brachytherapy mesh. Dr. Crimaldi said “The patient was a 12 year old male who was diagnosed with recurrent metastatic Wilms tumor (a type of childhood kidney tumor) in the pleural space of the lower aspect of his left chest. Prior to this he had been treated extensively, but nevertheless the cancer returned.

Due to previous irradiation of his chest (specifically whole lung irradiation), the patient was not a candidate for either SBRT (stereotactic radiosurgery) or proton therapy for treatment of this lesion. Although surgical removal of the tumor was possible, radiation therapy was needed in this case to treat the surgical bed.

I worked closely with IsoRay to design a custom mesh containing Cesium-131 sources and we were able to place the mesh at the time of surgery so as not to expose critical organs to high doses of radiation (lung, spinal cord, and aorta). Post-treatment dose calculations were performed confirming the delivery of dose to the resection bed and sparing of the critical structures. The patient recovered normally and has been discharged home.

The process of designing the treatment mesh was done with the assistance of the IsoRay team, and was quick and simple (done with the use of cross-sectional imaging). The mesh was designed, manufactured, and arrived for placement in less than 1 week. This device is an option that can provide treatment in areas of prior irradiation with a dose that is highly conformal and spares normal critical structures when other treatment modalities (such as external irradiation) are not possible.”

Dwight Babcock IsoRay’s Chairman and CEO stated: “When cancers become locally advanced, they recur frequently after surgery. Radiation is therefore performed, but the amount of radiation required to successfully treat the disease is often limited with existing technologies and has the potential to increase negative side effects to the patient. With the Cesium-131 seeded mesh we can get the optimal dose to the area of concern at the time of surgery — which we think is a real benefit for the patient.”

Recent innovations in cancer surgery have allowed surgeons to remove less healthy tissue than in years past. In these cases, however, radiation therapy becomes a critical addition to the treatment of the cancer. IsoRay Medical supplies multiple radiation based products that can be used at the time of surgery to deliver this needed radiation, ensuring direct irradiation of the cancer-involved target while minimizing the damaging effects of radiation on healthy tissues.

IsoRay Chairman and CEO Dwight Babcock noted: “We are very pleased to be working with innovative cancer physicians such as Dr. Crimaldi. We believe that collaboration between the radiation oncologist and the surgeon offers patients the best possible treatment.”

IsoRay is the exclusive manufacturer of Cesium-131. The pioneering brachytherapy therapy is one of the most significant advances in internal radiation therapy in 20 years. Cesium-131 allows for the precise treatment of many different cancers because of its unrivaled blend of high energy and its 9.7 day half-life (its unequaled speed in giving off therapeutic radiation).

In addition to its CMS codes, Cesium-131 is FDA-cleared and holds a CE mark for international sales in seed form for the treatment of brain cancer, prostate cancer, lung cancer, occular melanoma cancer, colorectal cancer, gynecologic cancer, head and neck cancer and other cancers throughout the body. The treatment can be deployed using several delivery methods including single seed applicators, implantable strands and seed sutured mesh, and several implantable devices including the GillaSite radiation therapy system, the world’s only liquid radiation balloon catheter device used in the treatment of brain cancer.

About IsoRay

IsoRay, Inc., through its subsidiary, IsoRay Medical, Inc., is the sole producer of Cesium-131 brachytherapy seeds, which are expanding brachytherapy options throughout the body. Learn more about this innovative Richland, Washington company and explore the many benefits and uses of Cesium-131 by visiting www.isoray.com.

Join us on Facebook/Isoray.  Follow us on Twitter@Isoray.

Safe Harbor Statement

Statements in this news release about IsoRay’s future expectations, including: the advantages of our products and their various delivery formats, the advantages of Cesium-131 in mesh form, whether adoption of our products will continue to increase, whether IsoRay will be able to continue to expand its base beyond prostate cancer, whether treatment of Wilms tumors using Cesium-131 will be successful in this and future cases, whether future studies of treatment of various cancers using our products will have favorable results, and all other statements in this release, other than historical facts, are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 (“PSLRA”). This statement is included for the express purpose of availing IsoRay, Inc. of the protections of the safe harbor provisions of the PSLRA. It is important to note that actual results and ultimate corporate actions could differ materially from those in such forward-looking statements based on such factors as physician acceptance, training and use of our products, our ability to successfully manufacture, market and sell our products, our ability to manufacture our products in sufficient quantities to meet demand within required delivery time periods while meeting our quality control standards, our ability to enforce our intellectual property rights, whether ongoing patient results with our products are favorable and in line with the conclusions of clinical studies and initial patient results, patient results achieved when our products are used for the treatment of cancers and malignant diseases beyond prostate, whether additional studies are released and support the conclusions of past studies, whether we, our distributors and our customers will successfully obtain and maintain all required regulatory approvals and licenses to market, sell and use our products in its various forms, successful completion of future research and development activities, the success of our sales and marketing efforts, changes in reimbursement rates, changes in laws and regulations applicable to our products, and other risks detailed from time to time in IsoRay’s reports filed with the SEC.

CONTACT:

IsoRay Medical

(509) 375-1202

Info@Isoray.com

(TKMR) Announces Completion of Underwritten Public Offering of Common Stock

VANCOUVER, British Columbia, March 18, 2014  — Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, today announced that it has completed its previously announced underwritten public offering of 2,125,000 shares of its common stock at a price of US$28.50 per share for aggregate gross proceeds of US$60,562,500, before deducting underwriting discounts and commissions and other estimated offering expenses. The underwriter has also been granted a 30-day option to purchase up to an additional 318,750 shares to cover over-allotments, if any, which would result in additional gross proceeds.

Tekmira anticipates using the net proceeds from this offering to develop and advance product candidates through clinical trials, as well as for working capital and general corporate purposes.

Leerink Partners LLC is acting as the sole manager for the offering.

The offering was made pursuant to an effective shelf registration statement previously filed with the U.S. Securities and Exchange Commission and a corresponding Canadian base shelf prospectus filed with the securities regulatory authority in each of the provinces of Canada, except Québec. All securities sold in the offering are being sold only in the United States. A prospectus supplement relating to the offering was filed with the SEC and with the securities regulatory authority in the province of British Columbia, Canada. Copies of the prospectus supplement relating to these securities may also be obtained from the offices of Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or via telephone at (800) 808-7525.

This press release does not constitute an offer to sell or the solicitation of an offer to buy any of these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale is not permitted.

About Tekmira

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing novel RNAi therapeutics and providing its leading lipid nanoparticle delivery technology to pharmaceutical partners. Tekmira has been working in the field of nucleic acid delivery for over a decade and has broad intellectual property covering LNPs. Further information about Tekmira can be found at www.tekmira.com. Tekmira is based in Vancouver, B.C.

Forward-Looking Statements and Information

This news release contains “forward-looking statements” or “forward-looking information” within the meaning of applicable securities laws (collectively, “forward-looking statements”). Forward-looking statements in this news release include statements about the option of an additional over-allotment to the underwriter; proposed use of proceeds; Tekmira’s strategy, future operations, clinical trials, prospects and the plans of management; RNAi (ribonucleic acid interference) product development programs; ongoing plans to advance therapeutics into multiple clinical trials; and expanding Tekmira’s pipeline of proprietary products in order to bring new treatments to patients and maximize value for shareholders.

With respect to the forward-looking statements contained in this news release, Tekmira has made numerous assumptions regarding, among other things: LNP’s status as a leading RNAi delivery technology. While Tekmira considers these assumptions to be reasonable, these assumptions are inherently subject to significant business, economic, competitive, market and social uncertainties and contingencies.

Additionally, there are known and unknown risk factors which could cause Tekmira’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements contained herein. Known risk factors include, among others: the overallotment option to the underwritten offering may not be exercised to the full amount anticipated, or at all; the proceeds of the offering may not be used for the purposes currently anticipated; Tekmira’s ability to obtain and protect intellectual property rights, and operate without infringing on the intellectual property rights of others; Tekmira’s research and development capabilities and resources will not meet current or expected demand; Tekmira’s products may not prove to be effective in the treatment of cancer and infectious diseases; the possibility that other organizations have made advancements in RNAi delivery technology that Tekmira is not aware of; the FDA will not approve the commencement of Tekmira’s planned clinical trials or approve the use of Tekmira’s products and generally, difficulties or delays in the progress, timing and results of clinical trials; the FDA may determine that the design and planned analysis of Tekmira’s clinical trials do not adequately address the trial objectives in support of Tekmira’s regulatory submissions; pre-clinical and clinical trials may be more costly or take longer to complete than anticipated; pre-clinical or clinical trials may not generate results that warrant future development of the tested drug candidate; and the possibility that Tekmira has not sufficiently budgeted for expenditures necessary to carry out planned activities.

A more complete discussion of the risks and uncertainties facing Tekmira appears in Tekmira’s continuous disclosure filings, which are available at www.sedar.com or at www.sec.gov. All forward-looking statements herein are qualified in their entirety by this cautionary statement, and Tekmira disclaims any obligation to revise or update any such forward-looking statements or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments, except as required by law.

CONTACT: Investors
         Jodi Regts
         Director, Investor Relations
         Phone: 604-419-3234
         Email: jregts@tekmirapharm.com

         Media
         David Ryan
         Longview Communications Inc.
         Phone: 416-649-8007
         Email: dryan@longviewcomms.ca

(QUIK) Announces KitKat Compliance of Ultra-low Power Sensor Hub

(DRAM) Signs Agreement with Advanced Micro Devices, Inc. to Expand Partnership

Dataram Corporation [NASDAQ: DRAM], a leading international manufacturer of computer memory and software products, announced that it has signed an Agreement with Advanced Micro Devices, Inc. (NYSE: AMD) to expand its memory manufacturing partnership from just North America to worldwide (excluding Russia, Ukraine, Kazakhstan, Belarus and Cyprus).

Since launching AMD Radeon™ Memory products on Newegg.com in April of 2013, Dataram has added Amazon, TigerDirect, Micro Center, Best Buy, NCIX and Canada Computer as selling partners in North America. Working in cooperation with AMD, Dataram will leverage its own sales personnel and established Manufacturers Representatives to penetrate the worldwide market.

To further the AMD Radeon brand, Dataram has been supporting AMD in establishing a formal AMP READY program. AMD Memory Profile Technology (AMP)provides memory performance enhancements exclusive to the AMD Radeon™ Memory product line. To date, four major motherboard companies including ASRock Inc., ASUS, GIGABYTE and MSI have participated and been approved for inclusion in this program. The AMD Radeon™ R9 2400 Gamer Series product is exclusively designed and engineered with AMD AMP Technology, which unleashes the full potential of the new AMD A10 Series APUs.¹

Orders have already been placed and shipped to Europe and Japan. Dataram will continue the worldwide rollout throughout the year.

ABOUT DATARAM CORPORATION

Founded in 1967, Dataram is a worldwide leader in the manufacture of high-quality computer memory and software products. Our products and services deliver IT infrastructure optimization, dramatically increase application performance and deliver substantial cost savings. Dataram solutions are deployed in 70 Fortune 100 companies and in mission-critical government and defense applications around the world. For more information about Dataram, visit www.dataram.com.

The information provided in this press release may include forward-looking statements relating to future events, such as the development of new products, pricing and availability of raw materials or the future financial performance of the Company. Actual results may differ from such projections and are subject to certain risks including, without limitation, risks arising from: changes in the price of memory chips, changes in the demand for memory systems, increased competition in the memory systems industry, order cancellations, delays in developing and commercializing new products and other factors described in the Company’s most recent Annual Report on Form 10-K, filed with the Securities and Exchange Commission, which can be reviewed at http://www.sec.gov.

Footnotes:

¹ Memory profiles are designed to boost system performance with preset memory profiles. AMP profiles are only available on supported AMD platforms and XMP profiles are only available on supported Intel platforms. The motherboard and the DDR3 memory module must be AMP or XMP-enabled in order to download preset profiles. Dataram’s product warranty does not cover damages caused by overclocking, even when overclocking is enabled via AMD or Intel hardware or software.

Check with motherboard manufacturer and system memory manufacturer to see if AMP or XMP are enabled.

A Dataram Corporation product. AMD brand, technology names and logos used under license from Advanced Micro Devices, Inc.

(CTP) Reports Placement Success Rate of 80%

Strongest Performance Measurement for Executive Search Firm

CTPartners (NYSE MKT: CTP), a leading global retained executive search firm, announced today its placement success rate of 80 percent for 2013, believed to be the highest in the executive search industry. The firm also reports that 75 percent of its searches are completed in an average of 100 days.

Brian Sullivan, Chief Executive Officer of CTPartners, said, “The AESC recently published its ‘Client Speaks’ report which states clients are looking for ‘more transparency and more metrics’ from their executive search professions. This is what CTPartners is built upon. Placement success rate is an important measure of the effectiveness of the search process. Our philosophy as a firm is to continue to consistently improve our placement success rate and always set the standard for reporting the data that clients need to measure the performance of their executive search firms.”

About CTPartners

CTPartners is a leading performance-driven executive search firm serving clients across the globe. Committed to a philosophy of partnering with its clients, CTPartners offers a proven record in C-Suite, senior executive, and board searches, as well as expertise serving private equity and venture capital firms.

With origins dating back to 1980, CTPartners serves clients with a global organization of more than 400 professionals and employees, offering expertise in board advisory services and executive recruiting services in the financial services, life sciences, industrial, professional services, retail and consumer, and technology, media and telecom industries. Headquartered in New York, CTPartners has 27 offices in 17 countries.

(PTX) Appoints Senior Vice President of Sales and Marketing

Pernix Therapeutics Holdings, Inc. (“Pernix” or the “Company”) (NASDAQ MKT: PTX), a specialty pharmaceutical company, today announced the appointment of Rick Shalaby as Senior Vice President of Sales and Marketing effective March 17, 2014.

Mr. Shalaby brings over twenty-three years of successful industry experience, including ten in executive leadership, to Pernix. His unique combination of big pharma, service provider and start-up pharmaceutical company experience combined with his motivational style, broad based background and ability to create and sustain positive cultures is a perfect fit for Pernix at this time in the company’s life cycle. Prior to joining Pernix, Mr. Shalaby spent eighteen years of his career at Merck and Co. Inc. where he held a variety of successful and progressively responsible positions in the areas of analytics, operations, market research, marketing, managed care and ultimately senior level positions in sales where he managed over two hundred sales professionals in specialty and primary care sales. His novel managed care pricing strategies, promotional message development and sales training expertise combined for many exceptional years of performance at Merck. From Merck, Mr. Shalaby moved on to PDI and in his tenure as vice president of sales was responsible for sales operations and for the creation and leadership of over eight distinct sales teams consisting of over seven hundred and fifty sales professionals. His work there provided him exposure to different methodologies utilized by his many clients and that knowledge facilitated successful product launches and ultimately positive sales results for each of his teams. He then moved to Amarin Pharmaceuticals where he was Vice President of Sales and efficiently built and led a three hundred person sales force to launch Amarin’s first commercial brand. Mr. Shalaby has also been on numerous advisory boards and is on the board of directors of Poly-Med Inc.

“Rick’s deep experience combined with his motivational style and high energy levels make him the ideal candidate to take our Pernix sales and marketing efforts to the next level as we launch Khedezla in April and plan for the relaunch of Silenor shortly thereafter. The management team and I are excited to have Rick on board and look forward to working with him to execute the new growth strategy for Pernix,” said Doug Drysdale, President and CEO of Pernix.

About Pernix Therapeutics Holdings, Inc.

Pernix Therapeutics is a specialty pharmaceutical company primarily focused on the sales, marketing, manufacturing and development of branded pharmaceutical products. The Company markets a portfolio of branded products, including: CEDAX®, an antibiotic for middle ear infections and a number of treatments for cough and cold conditions including ZUTRIPRO®, REZIRA® and VITUZ®. The Company also markets SILENOR, a non-narcotic product for the treatment of insomnia and KHEDEZLA, a treatment for major depressive disorder. The Company promotes its branded products to physicians through its Pernix sales force and markets its generic portfolio through its wholly owned subsidiaries, Cypress Pharmaceuticals and Macoven Pharmaceuticals. The Company’s wholly owned subsidiary, Pernix Manufacturing, manufactures and packages products for the pharmaceutical industry in a wide range of dosage forms. Founded in 1996, the Company is based in Houston, Texas.

Additional information about Pernix is available on the Company’s website located at www.pernixtx.com.

(MEEC) Announces $14 Million Commercial Contract for Mercury Emissions Control

(MOBI) Announces Strategic Partnership With China Unicom

HANGZHOU, China, March 17, 2014  — Sky-mobi Limited (“Sky-mobi” or the “Company”) (Nasdaq:MOBI), a leading mobile application store in China, today announced that the Company, through its controlling subsidiary Mopin Technology Co., Ltd., has recently entered into a strategic partnership with the Wo Store of China Unicom, the official application store of China’s second largest mobile operator. Under the terms of the agreement, Sky-mobi was designated as an official business partner of China Unicom to provide customized and tailor-made software services at China Unicom’s network of physical stores nation-wide.

This strategic partnership enables China Unicom to significantly improve the customer experience of purchasing a smartphone over the counter through offering quality customized software service from sales staff coached by Sky-mobi, marking another significant step in Sky-mobi’s overall cooperation with major telecom operators in China. Sky-mobi’s partnership with China Unicom initially covers its physical stores in the lucrative smartphone markets of Zhejiang, Guangxi and Shandong provinces, and will be expanded to cover Hubei, Heilongjiang, Hunan, Shanghai and Guangdong throughout 2014.

Michael Tao Song, Chairman and Chief Executive Officer of Sky-mobi stated, “We have been arduously working on this project since 2010 when we found through customer feedback that customers visiting the operator’s physical stores expected more than just assistance with choosing and purchasing a new phone. Rather our insights suggested they expect much more on the in-store service front, such as receiving advice on how to use smartphone applications effectively and smartly. Recognizing this consumer characteristic, we view our partnership with China Unicom as a great opportunity to better serve customers and assist telecom operators in promoting their monthly data-packages. The momentum of this strategy was evident last September, when we successfully deployed our customized and tailor-made software services solution for Zhejiang Mobile throughout most of their physical stores in Zhejiang province, allowing the carrier to benefit both from improved customer satisfaction and significantly-increased monthly data traffic consumption.

“Building on this previous experience, our partnership with China Unicom will also improve attraction and servicing of smartphone users, through providing advice and assistance with smartphone apps and services at China Unicom’s physical stores. Sky-mobi will benefit through leveraging, at no additional cost, China Unicom’s extensive physical store network, which has become an increasingly critical offline channel to immediately access new smartphone users. With this enhanced cooperation with telecom operators as well as our on-going smartphone initiatives, we’re very confident in our overall capabilities of expanding our user base and monetization opportunities over the long run.”

Safe Harbor Statement

This announcement contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by such terms as “may,” “will,” ”believes,” ”expects,” ”anticipates,” ”intends,” ”estimates,” “plans,” “continues” or other similar expressions, the negative of these terms, or other comparable terminology. Such statements, including statements relating to the Company’s business outlook, are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Potential risks and uncertainties include the effectiveness, profitability and marketability of the Company’s solutions; the Company’s limited operating history; measures introduced by the PRC government and mobile network operators aimed at mobile applications-related services; the Company’s revenue projections for future periods; the Company’s ability to maintain relationships with handset companies, content providers and payment service providers; its dependence on mobile service providers and mobile network operators for the collection of a substantial majority of its revenues; billing and transmission failures, which are often beyond the Company’s control; its ability to compete effectively; its ability to capture opportunities in the growing smart phone market; its ability to obtain and maintain applicable permits and approvals; general economic and business conditions; the volatility of the Company’s operating results and financial condition; the Company’s ability to attract or retain qualified senior management personnel and research and development staff; and other risks described in the Company’s filings with the Securities and Exchange Commission, including its annual report on Form 20-F filed on June 28, 2013. These forward-looking statements are based on current expectations, assumptions, estimates and projections about the Company and its industry. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law.

About Sky-mobi Limited

Sky-mobi Limited is a leading mobile application store in China. The Company works with handset companies to pre-install its Maopao mobile application store on handsets and with content providers to provide users with applications and content titles. Users of its Maopao store can browse, download and enjoy a range of applications and content, such as single-player games, mobile music and books on various mobile handsets with different hardware and operating system configurations. The Company’s mobile social network community in China, the Maopao Community, offers mobile social games, as well as applications and content with social network functions to its registered users. The Company is based in Hangzhou, China. For more information, please visit: www.sky-mobi.com.

CONTACT: Investor Relations Contact:
         Sky-mobi Limited
         Mr. John Bi, Chief Financial Officer
         Phone: + (86) 571-8777 0978 (Hangzhou, China)
         Email: investor.relations@sky-mobi.com

         ICR, Inc.
         Mr. Jeremy Peruski
         Phone: + (1) (646) -915-1615 (US)
         Email: investor.relations@sky-mobi.com

(CUR) Final Results Of Neuralstem Phase I Stem Cell Trial Published

ROCKVILLE, Md., March 17, 2014 /PRNewswire/ — Neuralstem, Inc. (NYSE MKT: CUR) announced that the final results from the Phase I safety trial using NSI-566 spinal cord stem cells in the treatment of amyotrophic lateral sclerosis (ALS or Lou Gehrig’s disease) were published in the peer-reviewed journal, “Annals of Neurology” http://onlinelibrary.wiley.com/doi/10.1002/ana.24113/full.  In “Intraspinal Neural Stem Cell Transplantation in Amyotrophic Lateral Sclerosis: Phase I Trial Outcomes,” results were updated from Phase I interim data, reported earlier, to include data from the last six patients in the trial. These six patients were the first to receive cervical stem cell transplants. Three of them were also the first to be transplanted along the length of their spines, in both the lumbar and the cervical regions. The results showed that NSI-566 human spinal cord stem cells can be safely transplanted in both the lumbar and cervical spinal cord segments, did not accelerate disease progression, and warrant further study on dosing and therapeutic efficacy. Furthermore, the researchers were able to identify potential therapeutic windows, suggesting that more injections, as well as multiple injections, are better and may increase both the length and the magnitude of the potential benefits. This is consistent with the hypothesized neuroprotective mechanism-of-action for this cell therapy.

Since concluding Phase I, the trial has progressed to Phase II at three centers, Emory University Hospital in Atlanta, Georgia, the ALS Clinic at the University of Michigan Health System, in Ann Arbor, Michigan, and Massachusetts General Hospital in Boston, Massachusetts, which treated its first patient in February. Treatment of three of the five Phase II cohorts has been completed.

“Although this was a Phase I trial, and functional outcome data were collected for the purpose of assessing safety, we performed secondary analyses of these data as a means to gain insight into how cellular transplantation affected disease progression rates and to inform outcome assessment approaches in future trial phases,” said Eva Feldman, MD, PhD, Director of the A. Alfred Taubman Medical Research Institute, Director of Research of the ALS Clinic at the University of Michigan Health System, principle investigator for the NSI-566/ALS trial and lead author. Dr. Feldman is also an unpaid consultant to Neuralstem.

“Pre-surgical disease progression rates for the various functional outcome measures were calculated to create slopes for each patient, so that we could determine if post-surgical data points, at 6, 9, 12 and 15 months, improved relative to predicted points. We also did analyses to determine which, if any, functional outcome assessment most closely correlated with the overall ALSFRS-R scores,” said Dr. Feldman. “Comparison of the outcome data to predicted outcome points in group E (patients who received both lumbar and cervical injections) revealed improvements in a significant number of measures at 6, 9, 12 and 15 months post-surgery. Overall, 50% of the patients in the trial showed improvement across multiple clinical measures at the same time points. We also found that a measure of grip strength correlated most closely with the overall ALSFRS-R scores.

Dr. Feldman added, “Finally, we conducted an analysis to identify the most biologically active period of the injected cells for the patients receiving both lumbar and cervical injections. This analysis reveals that the maximal periods of benefit correlate with the two surgical interventions. Importantly, as the ‘bell-shaped curve’ associated with each intervention is likely due to disease progression, increasing the total cell dose, and applying multiple applications of these stem cells, may increase both the length and magnitude of the potential benefit. We are of course exploring this very dosing regimen in our ongoing Phase II trial.”

“The completion of this Phase I study is a major milestone for the testing of intraspinal stem cell therapy for ALS,” said Jonathan Glass, MD, Professor of Neurology and Pathology, Emory University School of Medicine and Director of the Emory ALS Center, site principal investigator and a senior study author. “We have now shown that the procedure is safe for both lumbar and cervical injections, allowing us to move forward with an aggressive program to test whether this treatment will improve the course of disease for patients with ALS.”

“This peer-reviewed article is the first such report of cervical and dual-targeted intraspinal transplantation of neural stem cells in ALS subjects,” said Karl Johe, PhD, Neuralstem’s Chairman of the Board and Chief Scientific Officer. “We believe our cells offer a means to replace lost cells, provide neurotrophic support, and improve the diseased microenvironment.  This study demonstrates these factors, and that the cells and the novel surgical route of administration are safe and well-tolerated. Our ability to directly inject cells into the cervical regions of the spinal cord represents a significant advance in the field of cell therapy.

“We would like to thank the incredible teams at both Michigan and Emory who made this study possible, and who continue working with us today in our ongoing Phase II trial. We’d like to give special thanks to Dr. Jonathan Glass, Director of the Emory ALS Center, the Emory site principle investigator, and Dr. Nick Boulis, Associate Professor of Neurosurgery at Emory School of Medicine, the surgeon for all of the Phase I surgeries, and the inventor of the spinal-mounted stabilization and injection platform and floating cannula surgical devices used to deliver the cells,” concluded Dr. Johe.

About Neuralstem

Neuralstem’s patented technology enables the production of neural stem cells of the brain and spinal cord in commercial quantities, and the ability to control the differentiation of these cells constitutively into mature, physiologically relevant human neurons and glial cells. Neuralstem’s NSI-566 spinal cord-derived stem cell therapy is in Phase II clinical trials for amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s disease. Neuralstem has been awarded orphan status designation by the FDA for its ALS cell therapy.

In addition to ALS, the company is also targeting major central nervous system conditions with its NSI-566 cell therapy platform, including spinal cord injury and ischemic stroke. The company has received FDA approval to commence a Phase I safety trial in chronic spinal cord injury.

Neuralstem also maintains the ability to generate stable human neural stem cell lines suitable for systematic screening of large chemical libraries. Through this proprietary screening technology, Neuralstem has discovered and patented compounds that may stimulate the brain’s capacity to generate neurons, possibly reversing pathologies associated with certain central nervous system conditions.  The company has completed a Phase I safety trial evaluating NSI-189, its first neurogenic small molecule product candidate, for the treatment of major depressive disorder (MDD). Additional indications might include traumatic brain injury (TBI), Alzheimer’s disease, and post-traumatic stress disorder (PTSD).

For more information, please visit www.neuralstem.com or connect with us on Twitter, Facebook and LinkedIn

Cautionary Statement Regarding Forward Looking Information:

This news release may contain forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Neuralstem’s technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Neuralstem’s periodic reports, including the annual report on Form 10-K for the year ended December 31, 2013.